A common variant of endothelial nitric oxide synthase (Glu298Asp) is associated with collateral development in patients with chronic coronary occlusions

Table 1 Demographics and medical therapy at baseline by genotype

	Asp²⁹⁸ (n = 168)	Glu-Glu (n = 123)	All patients (n = 291)	p
Age, years	63 ± 11	62 ± 11	63 ± 11	0.92
Female gender, %	18	20	19	0.72
Body mass index, kg/m²	28.3 ± 4.7	27.8 ± 4.6	28.1 ± 4.6	0.32
Risk factors, %
Smoking	76	78	77	0.71
Hypercholesterolemia	76	81	78	0.29
Hypertension	54	55	55	0.86
Diabetes mellitus	35	37	36	0.80
Familial history of CAD	37	35	36	0.18
Clinical symptoms, %
Stable	73	78	75	0.35
Unstable	27	22	25
Angiographic data:
No. of vessels with > 50% stenosis, %
1 vessel	24	25	25
2 vessels	38	34	36	0.92
3 vessels	38	41	39
No. of vessels with total occlusion, %
1 vessel	85	83	84	0.61
2 vessels	15	17	16
Occluded LAD, %	38	29	34	0.12
Occluded Cx, %	17	22	19	0.32
Occluded RCA, %	60	66	62	0.27
Cardiovascular medications, %
ASA	78	78	78	0.96
ACE inhibitors	55	52	54	0.57
ARB	6	10	8	0.24
Beta-blockers	63	58	61	0.34
Nitrates	58	48	54	0.09
Calcium antagonists	24	31	27	0.20
Statins	63	58	61	0.34

Data are presented as percent of patients or mean value ± SD
CAD = coronary artery disease; MI, myocardial infarction
LAD = left anterior descending artery; Cx = circumflex; RCA = right coronary artery
ASA = acetylsalicylic acid; ACE = angiotensin-converting enzyme; ARB = angiotensin 2 receptor blockers.

ISSN: 1471-2261